NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Xaira Therapeutics

Xaira Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.xaira.com/

Last Round

Series A

Apr 23, 2024

Est. Valuation

$2.7B

Total Funding Raised

$1B

Company Overview

Xaira Therapeutics is a biotechnology company that leverages artificial intelligence to enhance drug discovery and development through comprehensive product development and data generation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Foundation

Keywords

drug discoverybiotechnologybiotechgenerative AIcomputational biologyfoundation modelfrontier AI labvirtual cell modelingtherapeutic pipelinebiomedical AItranslational scienceAI-native biotechdrug developmentprecision medicinein silico drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xaira Therapeutics Comparables

Compare Xaira Therapeutics with similar companies based on industry and business-model similarity.

Xaira Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Insitro
87%
Valo Health
83%
Generate Biomedicines
83%

Xaira Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 23, 2024

Key People

Founding team and executive leadership

Marc Tessier-Lavigne

Chief Executive Officer

Executive Team

Jeff Jonker

President COO

Executive Team

Paulo Fontoura

Chief Medical Officer

Executive Team

Xaira Therapeutics Investors

Notable investors and investment history

Xaira Therapeutics investors
InvestorRounds
Breyer CapitalSeries A
SV AngelSeries A
New Enterprise Associates (NEA)Series A
ARCH Venture PartnersSeries A
F-Prime CapitalSeries A
Risk and ReturnSeries A
Parker Institute for Cancer ImmunotherapySeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 18, 2026

    New model tests scaling laws in virtual cells.

  • Jun 17, 2025

    Launched X-Atlas/Orion, a large genome-wide Perturb-seq dataset.

Xaira Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Xaira Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xaira Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range202
Year Founded2023
Last FundingApr 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.